Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

13.44 3.07

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.89

Max

13.52

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.4M -14M
Pelnas, tenkantis vienai akcijai	-0.15
Darbuotojai	37
EBITDA	312K -12M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+134.25% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-266M 1.1B
Ankstesnė atidarymo kaina	10.37
Ankstesnė uždarymo kaina	13.44

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-27 23:51; UTC

"Bitcoin rises as Ethereum falls amid pivotal AI earnings reports, while U.S. credit rating remains stable and China's industrial profits soar."

2026-06-27 23:51; UTC

China's industrial profits rise 18.8% amid AI investments; U.S. credit rating affirmed at AA+ as markets brace for modest growth and pivotal Meta earnings report.

2026-06-27 23:51; UTC

Cryptocurrency market shows mixed signals as investors brace for key AI earnings reports and upcoming economic indicators amid cautious U.S. growth outlook.

2026-06-27 23:51; UTC

Mixed cryptocurrency performance reflects cautious investor sentiment ahead of key economic indicators and AI earnings reports, while U.S. credit rating remains stable amid inflation concerns.

2026-06-27 23:51; UTC

Bitcoin is trading higher since Friday's close, remaining flat during the current session. The price fluctuated within a routine range today.

2026-06-27 23:42; UTC

U.S. Labor Force Participation Rate Release on July 2, 2026: Market Cautious Amid Declining Employee Confidence and Legislative Changes Impacting Employment Dynamics.

2026-06-27 23:42; UTC

Market Awaits BoC Governor Macklem's Speech on Interest Rate Policy Amid Economic Uncertainties

2026-06-27 23:42; UTC

Market Eyes BoE Governor Bailey's July Speech for Insights on UK Interest Rates Amid Global Monetary Policy Shifts.

2026-06-27 23:42; UTC

Market Anticipates 0.3% Increase in U.S. Average Hourly Earnings Amid Wage Growth Concerns and Inflation Pressures Ahead of July Release.

2026-06-27 23:42; UTC

U.S. Unemployment Rate Release on July 2, 2026 Expected at 4.3%, Amid Concerns Over Employee Confidence and Potential Minimum Wage Legislation Impacting Markets

2026-06-27 23:42; UTC

Market Anticipates 114K Job Additions in Upcoming June NFP Report Amid Mixed Economic Sentiment and Inflation Concerns.

2026-06-27 23:42; UTC

Market Awaits Key Average Hourly Earnings Data Amidst Rising Inflation Concerns and Potential Federal Reserve Rate Implications on July 2, 2026.

2026-06-27 23:31; UTC

Mexican Consumer Confidence Expected to Remain Low Amid Economic Challenges Ahead of July 3 Data Release.

2026-06-27 23:11; UTC

ADP Employment Change Report Forecasts 118,000 Job Increase Amid Cautious Optimism in Labor Market Ahead of July Release.

2026-06-27 23:11; UTC

Correlated Moves

S&P 500 Index declines in after-market trading, reflecting cautious sentiment ahead of upcoming earnings reports from AI-linked companies like Meta.

2026-06-27 23:11; UTC

Correlated Moves

The Russell 2000 Index is lower in after-market trading, reflecting broader market sentiment amid upcoming earnings reports from AI-linked companies.

2026-06-27 23:11; UTC

Correlated Moves

The Dow Jones Index is lower in after-market hours, reflecting unusual trading activity and broader declines seen in the Russell 2000 Index.

2026-06-27 23:11; UTC

The FTSE 100 Index is lower in after-market hours, reflecting a dip since Friday's close. Anticipation of corporate earnings reports may influence market sentiment.

2026-06-27 23:11; UTC

Correlated Moves

The Nasdaq 100 Index is lower during after-market hours, continuing a downward trend since Friday's close amid broader market weakness and upcoming earnings anticipation.

2026-06-27 23:02; UTC

Canada's May GDP report set for June 30, with a projected growth of 0.4% amid mixed stock performance and trade uncertainties.

2026-06-27 22:32; UTC

Germany's June 30 inflation rate forecasted to rise by 0.1%, raising concerns over persistent inflation and potential ECB monetary policy shifts amid global economic pressures.

2026-06-27 22:32; UTC

Germany's June 2026 Inflation Rate Release Expected at 2.5% Amid Rising Global Price Pressures and Cautious Market Sentiment

2026-06-27 22:32; UTC

Japan's Tankan Large Manufacturers Index set for June 30, with cautious market sentiment amid stock declines and mixed economic signals.

2026-06-27 22:32; UTC

South Africa's Upcoming Balance of Trade Data Expected to Show Significant Shift Amid Rising Imports and Mixed Export Performance

2026-06-27 22:21; UTC

Brazil's Central Bank to Provide Key Insights on Interest Rate Outlook Amid Rising Global Pressures in June 29 Readout.

2026-06-27 22:11; UTC

Japan's Industrial Production Expected to Rise 1.1% in May Amid Mixed Market Sentiment and Economic Concerns

2026-06-27 22:02; UTC

South Korea's June 2026 Inflation Rate Release Sparks Market Caution Amid Rising Price Pressures and Regional Economic Concerns.

2026-06-27 21:51; UTC

Japan's Retail Sales YoY data for May set to release on June 28, with a projected growth of 3.2% amid mixed market sentiment and inflation concerns.

2026-06-27 21:51; UTC

Japan's Unemployment Rate Expected to Stabilize at 2.5% Amid Mixed Economic Sentiment and Market Volatility

2026-06-27 21:41; UTC

Cautious Sentiment Surrounds Upcoming Ai Group Industry Index Release Amid Ongoing Economic Challenges in Australia

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

134.25% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD 134.25%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.